Comparison of intrathecal chemotherapy for leptomeningeal carcinomatosis of a solid Tumor: Methotrexate alone versus methotrexate in combination with cytosine arabinoside and hydrocortisone

Japanese Journal of Clinical Oncology

Volumn 33, Issue 12, 2003, Pages 608-612

  Kim, Dae Young ^a   Lee, Keun Wook ^a   Yun, Tak ^a   Park, Sook Ryun ^a   Jung, Joo Young ^a   Kim, Dong Wan ^a   Kim, Tae You ^a   Heo, Dae Seog ^a   Bang, Yung Jue ^a   Kim, Noe Kyeong ^a  

^a Seoul National University College of Medicine   (South Korea)

Author keywords

Cytarabine; Meningeal neoplasms; Methotrexate; Spinal injections

Indexed keywords

CYTARABINE; FOLIC ACID; HYDROCORTISONE; LIVER ENZYME; METHOTREXATE; ANTINEOPLASTIC AGENT;

ADENOCARCINOMA; ADOLESCENT; ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER LOCALIZATION; CANCER PATIENT; CANCER SURVIVAL; CARCINOMATOUS MENINGITIS; CONTROLLED STUDY; DRUG EFFICACY; DRUG RESPONSE; FEMALE; HUMAN; LEUKOPENIA; LIVER TOXICITY; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; NEUROTOXICITY; SOLID TUMOR; STATISTICAL ANALYSIS; STOMACH CANCER; SURVIVAL TIME; COMPARATIVE STUDY; DRUG ADMINISTRATION; INTRASPINAL DRUG ADMINISTRATION; MENINGIOMA; MIDDLE AGED; MORTALITY; PATHOLOGY; RETROSPECTIVE STUDY; SMALL CELL CARCINOMA; SURVIVAL RATE;

ADENOCARCINOMA; ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, SMALL CELL; CYTARABINE; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; HYDROCORTISONE; INJECTIONS, SPINAL; MALE; MENINGEAL NEOPLASMS; METHOTREXATE; MIDDLE AGED; RETROSPECTIVE STUDIES; SURVIVAL RATE;

EID: 18544397596     PISSN: 03682811     EISSN: 14653621     Source Type: Journal    
DOI: 10.1093/jjco/hyg118     Document Type: Article

References (10)

1. Wasserstrom WR, Glass JP, Posner JB. Diagnosis and treatment of leptomeningeal metastases from solid tumors: Experience with 90 patients. Cancer 1982;49:759-72.
2. Eberth CJ. Zur Entwicklung des Epitheliomas dur Pia under der Lung. Virchow's Arch 1870;49:51-63 (in German).
3. Giannone L, Greco FA, Hainsworth JD. Combination intraventricular chemotherapy for meningeal neoplasia. J Clin Oncol 1986;4:68-73.
4. Hitchins RN, Bell DR, Woods RL, Levi JA. A prospective randomized trial of single-agent versus combination chemotherapy in meningeal carcinomatosis. J Clin Oncol 1987;5:1655-62.
5. Bleyer WA, Drake JC, Chabner BA. Neurotoxicity and elevated cerebrospinal-fluid methotrexate concentration in meningeal leukemia. N Engl J Med 1973;289:770-3.
6. Sculier JP. Treatment of meningeal carcinomatosis. Cancer Treat Rev 1985;12:95-104.
7. Grossman SA, Krabak MJ. Leptomeningeal carcinomatosis. Cancer Treat Rev 1999;25:103-19.
8. Sullivan MP, Moon TE, Trueworthy R, Vietti TJ, Humphrey GB, Kemp D. Combination intrathecal chemotherapy for meningeal leukemia: Two versus three drugs. Blood 1977;50:471-9.
9. Glantz MJ, Cole BF, Recht L, Akerley W, Mills P, Saris S, et al. High-dose intravenous methotrexate for patients with nonleukemic leptomeningeal cancer: Is intrathecal chemotherapy necessary? J Clin Oncol 1998;16: 1561-7.
10. Jaeckle KA, Batchelor T, O'Day SJ, Phuphanich S, New P, Lesser G, et al. An open label trial of sustained-release cytarabine (DepoCyt) for the intrathecal treatment of solid tumor neoplastic meningitis. J Neurooncol 2002;57:231-9.